Recent Articles

• AB Science Advances AML Treatment with New Phase II Study Approval
• Aedifica NV/SA Reports Strong Financial Growth in 2025
• Sanoma Corporation Reports Strong Operational EBIT Growth
• Exosens Reports Robust H1 2025 Growth Amid Defense Market Surge
• Novaturas Group's Upcoming Financial Results Webinar Details
• Danone's Strong Financial Performance in the First Half of 2025
• Spotify's Pricing Strategy Explained: Balancing Value and Growth
• Danone's Half-Year Performance Highlights: Growth and Strategy
• Rocky Brands Stock Skyrockets Following Impressive Earnings Report
• Exosens Progresses with Strong Results and Strategic Acquisition
• Sanoma Corporation's Strong Performance Enhances Learning Capabilities
• Aedifica's Financial Growth: 2025 Half-Year Performance Overview
• Soul App Revolutionizes Social Experience with AI at WAIC
• Sandoz Explores Acquisition of Just-Evotec Biologics
• Fiverr International Ltd Reports Impressive Q2 2025 Earnings
• Photocure ASA Reports Impressive Growth in Q2 2025 Results
• Photocure ASA Sees Growth in Hexvix/Cysview Revenue Performance
• Nexans Begins Search for New CFO Amid Leadership Changes
• Sanofi's Revolutionary Approach in Treating Multiple Myeloma
• Worldline Unveils Dynamic Management Team for Future Growth
• Fiverr Q2 2025 Report Highlights Growth Amid AI Expansion
• Vopak's Remarkable First Half 2025 Performance Boosts Outlook
• Sandoz Moves Forward with Acquisition of Just-Evotec Biologics
• IMCD Achieves Maiden Financial Success with 275 Million EBITA
• Photocure ASA Reports Impressive Q2 Growth and Outlook
• Ascom Partners with SEC-COM to Enhance German Healthcare Solutions
• Nexans Exceeds Expectations as 2025 Guidance is Enhanced
• Capgemini Reports Mixed H1 2025 Results Amid Global Challenges
• Worldline's H1 2025 Results: A Comprehensive Overview
• JDE Peet's Shows Robust Growth in First Half Financial Season
• JDE Peet’s Reports Strong Half-Year Financial Results
• Idorsia's Financial Strength Shines as QUVIVIQ Sales Surge
• Solvay's Financial Review: Navigating Challenges in 2025
• Melexis Reports Impressive Q2 2025 Financial Performance
• Sanofi’s Breakthrough Antibody Awarded Orphan Drug Status for Myeloma
• Nexans Begins Search for New Chief Financial Officer Amid Changes
• Vopak Sees Growth in HY1 2025, Upgrades Full-Year Projections
• Worldline's Financial Performance Insights for H1 2025
• Capgemini's Mid-Year 2025 Results Showcase Growth Amid Challenges
• Worldline's Revamped Leadership Team Driving Strategic Change
• IMCD N.V. Achieves Impressive EBITA Growth in 2025
• Innovations in Furniture Design Set for Shanghai in 2025
• NOR Flash Market Set for Growth: Insights & Forecast to 2034
• Analyzing the Impact of Trump's EU Trade Agreement
• Furniture China 2025: Innovations and Trends in Design
• Hepsor AS Reports Significant Revenue Growth in Q2 2025
• Hepsor AS Reports Strong Revenue Growth in Q2 Performance
• Analysis of Trends in Securities Class Actions for 2025
• Transforming U.S. Textile Waste into Opportunities Abroad
• Larimar Therapeutics Sets Public Offering Pricing at $3.20/share